Citation:
Cancer Metab. 2014;2(Suppl 1):P16. doi:10.1186/2049-3002-2-S1-P16
Abstract:
Of the 230,000 new cases of invasive breast cancer diagnosed annually, 70% express the estrogen receptor-α and may be treated with anti-estrogen therapies. While these drugs induce clinical benefit, over 50% will develop resistance. Recently, we have determined a key role of the unfolded protein response endoplasmic reticulum protein chaperone, glucose-regulated protein 78 (GRP78), in mediating anti-estrogen resistance. We now expand the role of GRP78 to include regulation of lipid metabolism.
Epub:
Not Epub
Link to Publication:
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4073063/
Organism or Cell Type:
cell culture, tumors: LCC1 cells